Takeda in Pact for Celiac Disease Therapy
By

Takeda Pharmaceutical has entered into an agreement with PvP Biologics, a San Diego-headquartered biopharmaceutical company, for the development of KumaMax, a compound under development for treating celiac disease. KumaMax is a recombinant enzyme designed to break down the immune-reactive parts of gluten in the stomach, avoiding the symptoms and damage done from accidental gluten ingestion, according to PvP.

Under the agreement, PvP will conduct all research and development through Phase I proof-of-principle studies per a pre-defined development plan. Takeda will fund $35 million for PvP’s expenses related to the plan in exchange for an exclusive option to acquire PvP following receipt of a pre-defined data package. Upon PvP’s completion of the development plan, Takeda may exercise its option to acquire PvP by paying an undisclosed fee as well as development and regulatory milestones.

Source: Takeda Pharmaceutical

Leave a Reply

Your email address will not be published.